Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/32648
Title: Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial.
Austin Authors: Sternberg, Cora N;Davis, Ian D;Mardiak, Jozef;Szczylik, Cezary;Lee, Eunsik;Wagstaff, John;Barrios, Carlos H;Salman, Pamela;Gladkov, Oleg A;Kavina, Alexander;Zarbá, Juan J;Chen, Mei;McCann, Lauren;Pandite, Lini;Roychowdhury, Debasish F;Hawkins, Robert E
Affiliation: From the Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy; Ludwig Oncology Unit, Austin Hospital, Melbourne, Australia; National Oncological Institute, Klenová, Bratislava, Slovakia; Department of Oncology, Military Institute of Medicine, Warsaw, Poland; Department of Urology, Seoul National University College of Medicine, Seoul, Korea; The South West Wales Cancer Institute, Singleton Hospital, Swansea; Cancer Research UK, Department of Medical Oncology, University of Manchester; Christie Hospital National Health Services Foundation Trust, Manchester, United Kingdom; Oncology Research Unit, Oncology Service, Hospital Sao Lucas, Pontifícia Universidade Católica do Rio Grande do Sol, Porto Alegre, Brazil; Division of Medical Oncology and Hematology, Fundación Arturo López Pérez, Santiago, Chile; Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation; Krankenhaus Heitzing, mit Neurologischem Zentrum Rosenhugel, Vienna, Austria; Centro Médico San Roque, Tucumán, Argentina; GlaxoSmithKline, Collegeville, PA; and GlaxoSmithKline, Research Triangle Park, NC.
Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy
Medical Oncology
National Oncological Institute, Klenová, Bratislava, Slovakia
Department of Oncology, Military Institute of Medicine, Warsaw, Poland
Department of Urology, Seoul National University College of Medicine, Seoul, Korea
The South West Wales Cancer Institute, Singleton Hospital, Swansea
Cancer Research UK, Department of Medical Oncology, University of Manchester
Christie Hospital National Health Services Foundation Trust, Manchester, United Kingdom
Oncology Research Unit, Oncology Service, Hospital Sao Lucas, Pontifícia Universidade Católica do Rio Grande do Sol, Porto Alegre, Brazil
Division of Medical Oncology and Hematology, Fundación Arturo López Pérez, Santiago, Chile
Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation
Krankenhaus Heitzing, mit Neurologischem Zentrum Rosenhugel, Vienna, Austria
Centro Médico San Roque, Tucumán, Argentina; GlaxoSmithKline, Collegeville, PA
Issue Date: 10-Apr-2023
Publication information: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2023; 41(11)
Abstract: Pazopanib is an oral angiogenesis inhibitor targeting vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-Kit. This randomized, double-blind, placebo-controlled phase III study evaluated efficacy and safety of pazopanib monotherapy in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). Adult patients with measurable, locally advanced, and/or metastatic RCC were randomly assigned 2:1 to receive oral pazopanib or placebo. The primary end point was progression-free survival (PFS). Secondary end points included overall survival, tumor response rate (Response Evaluation Criteria in Solid Tumors), and safety. Radiographic assessments of tumors were independently reviewed. Of 435 patients enrolled, 233 were treatment naive (54%) and 202 were cytokine pretreated (46%). PFS was significantly prolonged with pazopanib compared with placebo in the overall study population (median, PFS 9.2 v 4.2 months; hazard ratio [HR], 0.46; 95% CI, 0.34 to 0.62; P < .0001), the treatment-naive subpopulation (median PFS 11.1 v 2.8 months; HR, 0.40; 95% CI, 0.27 to 0.60; P < .0001), and the cytokine-pretreated subpopulation (median PFS, 7.4 v 4.2 months; HR, 0.54; 95% CI, 0.35 to 0.84; P < .001). The objective response rate was 30% with pazopanib compared with 3% with placebo (P < .001). The median duration of response was longer than 1 year. The most common adverse events were diarrhea, hypertension, hair color changes, nausea, anorexia, and vomiting. There was no evidence of clinically important differences in quality of life for pazopanib versus placebo. Pazopanib demonstrated significant improvement in PFS and tumor response compared with placebo in treatment-naive and cytokine-pretreated patients with advanced and/or metastatic RCC.
URI: https://ahro.austin.org.au/austinjspui/handle/1/32648
DOI: 10.1200/JCO.22.02622
ORCID: 
Journal: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Start page: 1957
End page: 1964
PubMed URL: 37018920
ISSN: 1527-7755
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

22
checked on Oct 15, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.